Please login to the form below

Not currently logged in
Email:
Password:

CMPT announces CEO and loan investment

CMP Therapeutics has announced that Dr Neill Moray Mackenzie will become CEO and that the company will receive a €1.5m convertible loan investment

CMP Therapeutics (CMPT) has appointed Dr Neill Moray Mackenzie to the role of CEO, replacing Dr Bruce Savage, who leaves CMPT to concentrate on his other portfolio companies.

Dr Mackenzie brings to CMPT experience at executive board level in both the biotechnology and pharmaceutical industries. He has held roles at Cambridge Genetics, Oxford Biomedica, Avidex (now Immunocore) and, most recently, was senior vice president for business development and corporate strategy at Medigene and CEO of Roji (London).

Dr MacKenzie was also a departmental head in vaccine R&D at Wellcome and a Wellcome Lecturer in immunology at the University of London.

In addition, CMPT has announced that the company will receive an injection of €1.5m in the form of a convertible loan from Inventages Venture Capital, which will be used to support continuing operations and the upcoming clinical trial of its lead product for the common cold.

Since 2005 CMPT has been supported solely by investments from London-based Inventages Venture Capital and New Zealand-based BioPacificVentures.

2nd August 2010

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Dovetail

We’re a specialist health consultancy that supports companies, healthcare professionals and patients to work hand in hand with a common...

Latest intelligence

Top-10 Reasons Why You Should be Adding Asynchronous Virtual Touchpoints Between Your Real-time Meetings
...
Flu
Influenza – the risk to vulnerable populations
Why we can't get complacent about flu vaccination...
dementia
Alzheimer’s Research UK highlights socio-economic inequalities in dementia risk
The charity aims to improve the number of women participating in dementia research and grow awareness of dementia risk factors...